12 – 16 August, 2017
For the first time, PharmSintez.Lab participated in 2nd World Rhenium congress, which this year took part in Coimbatore (India).
During the whole week out team had a chance to visit all main highlights of the conference. The first was the meeting of the Society of Nuclear medicine (12-13 of August), which had predominantly educational purposes, bringing together clinicians and the nuclear medicine physicians from all over India, so they could have a chance to update scientific knowledge, exchange ideas, discuss and develop better protocols for the management of patients.
The second was The 2nd World Congress on Rhenium-188 (14-15 of August), which took place at Kovai Medical Centre and Hospital (KMCH) in Coimbatore. The aim of the congress was to develop a community to discuss the benefits of 188Re for therapy and to catalyze increased clinical applications of some well established 188Re radiopharmaceuticals. Nuclear medicine physicians and scientists working in radiochemistry, radiopharmacy, radiation biology and radiation dosimetry had a chance to discuss many important topics, such as current methods for the preparation of ‘robust’ 188Re radiopharmaceuticals, radiation protection in nuclear medicine and many other.
Finally, the last two days were dedicated to the World Theragnostics Academy meeting (15-16 of August), which had a mission to impart continuous professional development, educate and instill a system for training professionals aimed at the progress of nuclear medicine, and to support teaching and learning excellence in the nuclear medicine community. WTA was composed of faculty, instructional staff, and graduate students who have been recognized by their peers for sustained, demonstrated teaching excellence, which helps faculty, staff, and students across the world to update their knowledge by creating an informal channel for disbursement of knowledge without geographical barriers.
As one of the main sponsors of the conference, Pharm-Sintez.lab represented their latest developments in nuclear medicine, such as radiopharmaceuticals Rezoskan, 99mTc and Zoleren, 188Re. Additionally, the company showed latest progression within nuclear medicine diagnostics, introducing participants to new PET precursors.
All of the products received a wide resonance and a very high attention from international partners.
Our team would like to say thank you to all of the participants for a very warm welcome, great organization and informative communication. We hope to continue our collaboration and looking forward to working together.